MA52390A - Anticorps anti-coronavirus et procédés d'utilisation - Google Patents

Anticorps anti-coronavirus et procédés d'utilisation

Info

Publication number
MA52390A
MA52390A MA052390A MA52390A MA52390A MA 52390 A MA52390 A MA 52390A MA 052390 A MA052390 A MA 052390A MA 52390 A MA52390 A MA 52390A MA 52390 A MA52390 A MA 52390A
Authority
MA
Morocco
Prior art keywords
methods
coronavirus antibodies
coronavirus
antibodies
Prior art date
Application number
MA052390A
Other languages
English (en)
French (fr)
Inventor
Olubukola Abiona
Jeffrey Streetman Boyles
Qing Chai
Kizzmekia Corbett
Julian Davies
Ester Falconer
Denisa Foster
Christopher Carl Frye
Ganapathy Gopalrathnam
Barney Graham
Jörg Hendle
Kevin Jepson
Bryan Edward Jones
Wing-Pui Kong
Julie Ledgerwood
John Mascola
Krithika Muthuraman
Anna Pustilnik
John Michael Sauder
Wei Shi
Lingshu Wang
Kathryn Westendorf
Stefanie Zentelis
Yi Zhang
Original Assignee
Abcellera Biologics Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcellera Biologics Inc, Us Health filed Critical Abcellera Biologics Inc
Publication of MA52390A publication Critical patent/MA52390A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
MA052390A 2020-03-09 2020-12-14 Anticorps anti-coronavirus et procédés d'utilisation MA52390A (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062987313P 2020-03-09 2020-03-09
US202063010999P 2020-04-16 2020-04-16
US202063030530P 2020-05-27 2020-05-27
US202063036089P 2020-06-08 2020-06-08
US202063080351P 2020-09-18 2020-09-18
US202063085042P 2020-09-29 2020-09-29
US202063116483P 2020-11-20 2020-11-20

Publications (1)

Publication Number Publication Date
MA52390A true MA52390A (fr) 2021-10-27

Family

ID=73835506

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052390A MA52390A (fr) 2020-03-09 2020-12-14 Anticorps anti-coronavirus et procédés d'utilisation

Country Status (14)

Country Link
US (5) US20210292393A1 (cg-RX-API-DMAC7.html)
EP (2) EP3878862A3 (cg-RX-API-DMAC7.html)
JP (2) JP2023517234A (cg-RX-API-DMAC7.html)
KR (2) KR102535195B1 (cg-RX-API-DMAC7.html)
CN (2) CN116096742A (cg-RX-API-DMAC7.html)
AU (2) AU2020435452A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022017986A2 (cg-RX-API-DMAC7.html)
CA (2) CA3171237A1 (cg-RX-API-DMAC7.html)
GB (1) GB2593023A (cg-RX-API-DMAC7.html)
IL (2) IL296224A (cg-RX-API-DMAC7.html)
MA (1) MA52390A (cg-RX-API-DMAC7.html)
MX (2) MX2022011142A (cg-RX-API-DMAC7.html)
TW (2) TWI782366B (cg-RX-API-DMAC7.html)
WO (2) WO2021183195A1 (cg-RX-API-DMAC7.html)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES3063952T3 (en) * 2015-05-18 2026-04-21 Agensys Inc Antibodies that bind to axl proteins
WO2016187354A1 (en) * 2015-05-18 2016-11-24 Agensys, Inc. Antibodies that bind to axl proteins
US20180128545A1 (en) 2016-11-08 2018-05-10 Berry Metal Company Modular furnace cooling wall
CA3131096A1 (en) 2019-04-05 2020-10-08 Chi-Huey Wong Sialidase-resistant saccharide and method of making and using the same
AU2021225827B2 (en) * 2020-02-24 2024-12-19 Institute Of Microbiology, Chinese Academy Of Sciences Humanized monoclonal antibody for 2019 novel coronavirus and use thereof
WO2021195418A1 (en) 2020-03-26 2021-09-30 Vanderbilt University Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2)
CR20220552A (es) 2020-04-02 2023-01-17 Regeneron Pharma Anticuerpos contra glicoproteína de espícula anti-sars-cov-2 y fragmentos de unión al antígeno
CA3182526A1 (en) 2020-05-08 2021-11-11 Academia Sinica Chimeric influenza vaccines
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
PH12022553106A1 (en) * 2020-05-17 2023-11-20 Astrazeneca Uk Liimited Sars-cov-2-antibodies and methods of selecting and using the same
MX2022014598A (es) 2020-05-26 2023-03-31 Regeneron Pharma Anticuerpos anti-glicoproteína espicular sars-cov-2 y fragmentos de unión al antígeno.
CR20220660A (es) 2020-06-03 2023-02-17 Regeneron Pharma Métodos para tratar o prevenir infecciones por sars-cov2 y covid-19 con anticuerpos de glicoproteína espícular anti-sars-cov-2
US20220003779A1 (en) * 2020-07-03 2022-01-06 The Research Foundation For The State University Of New York Methods for qualitative and quantitative analysis of a plurality of biomarkers
EP4182687A4 (en) * 2020-07-20 2024-09-11 Bio-Rad Laboratories, Inc. IMMUNOASSAY FOR SARS-COV-2 NEUTRALISING ANTIBODIES AND MATERIALS THEREFOR
US20250263468A1 (en) * 2020-07-24 2025-08-21 Celltrion Inc. Binding molecule having neutralizing activity against coronavirus superfamily
WO2022035918A1 (en) * 2020-08-11 2022-02-17 Eli Lilly And Company Anti-sars-cov-2 antibodies
US11919958B2 (en) 2020-08-19 2024-03-05 Xencor, Inc. Anti-CD28 compositions
PE20231507A1 (es) * 2020-10-02 2023-09-26 Lilly Co Eli Metodos para reducir el contenido de proteinas de la celula huesped en procesos de purificacion de anticuerpos y composiciones de anticuerpos que tienen un contenido reducido de proteinas de la celula huesped
WO2022082217A1 (en) 2020-10-16 2022-04-21 Eureka Therapeutics, Inc. Compositions for preventing or treating viral and other microbial infections
WO2022162587A1 (en) * 2021-01-27 2022-08-04 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
CN115141270A (zh) * 2021-03-29 2022-10-04 深圳市康麦生物技术有限公司 特异性结合新型冠状病毒的抗体
WO2022221837A2 (en) 2021-04-12 2022-10-20 Academia Sinica Improved coronavirus vaccine
JP2024518335A (ja) * 2021-04-26 2024-05-01 アンスティチュ パスツール SARS-CoV-2に対するヒト中和モノクローナル抗体、及びそれらの使用
CN113461810B (zh) * 2021-05-17 2021-12-28 深圳市福田区格物智康病原研究所 一种抗新型冠状病毒刺突蛋白的全人源单克隆抗体及其应用
EP4341289A1 (en) * 2021-05-18 2024-03-27 Christian-Albrechts-Universität zu Kiel Co-stimulatory multispecific antibodies
CN117897173A (zh) * 2021-06-08 2024-04-16 伊莱利利公司 含有2019新型冠状病毒抗体的药物制剂
WO2022263638A1 (en) * 2021-06-17 2022-12-22 Centre Hospitalier Universitaire Vaudois (C.H.U.V.) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
EP4370210A1 (en) 2021-07-14 2024-05-22 Regeneron Pharmaceuticals, Inc. Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments
WO2023285620A2 (en) * 2021-07-14 2023-01-19 Alchemab Therapeutics Ltd. Compositions and methods for targeting viral proteins
US12600764B2 (en) 2021-08-27 2026-04-14 International Business Machines Corporation Antigen-binding proteins targeting coronavirus (COV) variants
CN113735969B (zh) * 2021-09-20 2023-05-12 中国人民解放军军事科学院军事医学研究院 一种全人源抗新冠病毒广谱高中和活性单克隆抗体及应用
TW202334429A (zh) 2021-10-01 2023-09-01 中央研究院 Sars-cov-2棘蛋白特異性抗體及其用途
EP4413122A4 (en) * 2021-10-07 2026-04-08 Seqirus Pty Ltd ANTI-SARS-CoV-2 ANTIBODIES AND THEIR USES I
US20240425567A1 (en) * 2021-10-08 2024-12-26 Invivyd, Inc. Pharmaceutical formulations comprising anti-coronavirus s protein antibodies and uses thereof
US20240327505A1 (en) * 2021-10-22 2024-10-03 University Of Vermont And State Agricultural College Antibodies to coronavirus sars-cov-2
WO2023076419A2 (en) * 2021-10-27 2023-05-04 Twist Bioscience Corporation Sars-cov-2 antibodies and methods of use
WO2023079137A1 (en) * 2021-11-05 2023-05-11 Katholieke Universiteit Leuven Neutralizing anti-sars-cov-2 human antibodies
US20250034234A1 (en) * 2021-11-09 2025-01-30 Rhode Island Hospital Predicting covid-19 antibodies among survivors with deep rna sequencing
WO2023084055A1 (en) * 2021-11-12 2023-05-19 Rq Biotechnology Limited Compositions
CA3237165A1 (en) * 2021-11-19 2023-05-25 Jeng-Horng Her Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy
EP4183800A1 (en) * 2021-11-19 2023-05-24 Medizinische Hochschule Hannover Novel sars-cov-2 neutralizing antibodies
CN116217711A (zh) * 2021-12-03 2023-06-06 广东菲鹏生物有限公司 一种SARS-CoV-2检测方法和试剂盒
KR102793620B1 (ko) 2021-12-09 2025-04-09 한국화학연구원 사스-코로나바이러스-2 뉴클레오캡시드 단백질에 대한 단클론 항체 및 이의 용도
WO2023133338A2 (en) * 2022-01-10 2023-07-13 University Of Pittsburgh – Of The Commonwealth System Of Higher Education Molecules that bind to neutrophil elastase polypeptides
KR20240137083A (ko) * 2022-01-28 2024-09-19 에베크 인코포레이티드 변이주 교차성을 갖는 항SARS-CoV-2 인간 중화 항체 및 그의 항원 결합성 단편
US20250145691A1 (en) * 2022-02-15 2025-05-08 Board Of Regents, The University Of Texas System Human monoclonal antibodies targeting the s2 subunit of the sars-cov-2 spike protein
TW202342510A (zh) 2022-02-18 2023-11-01 英商Rq生物科技有限公司 抗體
IL314993A (en) 2022-02-23 2024-10-01 Xencor Inc Anti-cd28 x anti-psma antibodies
WO2023159316A1 (en) * 2022-02-28 2023-08-31 Immune Biosolutions Inc. Formulation of anti-sars-cov-2 neutralizing antibodies and uses thereof
US20260035438A1 (en) * 2022-03-04 2026-02-05 The Scripps Research Institute Human broadly neutralizing antibodies against betacoronaviruses
WO2023178182A1 (en) * 2022-03-16 2023-09-21 10X Genomics, Inc. Compositions and methods for detection and treatment of coronavirus infection
CN115286712B (zh) * 2022-03-18 2024-09-27 北京百普赛斯医学检验实验室有限公司 新型冠状病毒Delta突变株特异性抗体及其应用
WO2023183848A2 (en) * 2022-03-25 2023-09-28 The Rockefeller University Anti-sars-cov-2 antibodies and methods of use thereof
EP4505179A4 (en) * 2022-04-01 2026-06-24 Invivyd Inc Anti-SARS-CoV-2 antibodies and their uses
CN114656555B (zh) * 2022-04-08 2024-03-19 广州医科大学附属第一医院(广州呼吸中心) 抗SARS-CoV-2病毒的中和抗体及其制备方法和应用
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS
CA3256035A1 (en) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. COMPOSITIONS FOR PREVENTING OR TREATMENT OF CORONAVIRUS INFECTIONS
WO2024025940A1 (en) * 2022-07-26 2024-02-01 Ap Biosciences, Inc. Sars-cov-2 antibodies and bispecific antibodies
CN116143910B (zh) * 2022-10-12 2026-03-24 水木未来(北京)科技有限公司 靶向SARS-CoV-2刺突蛋白的纳米抗体及其应用
KR20250122456A (ko) * 2022-11-01 2025-08-13 프로비던스 헬스 앤드 서비시즈 - 오레곤 Fas 리간드에 특이적인 단일클론 항체 및 이의 용도
WO2024133564A1 (en) 2022-12-21 2024-06-27 National University Of Singapore Sars-cov-2 spike protein-binding molecules
WO2024187177A2 (en) * 2023-03-09 2024-09-12 The Johns Hopkins University Recombinant antibody for the treatment of extracellular dna overload
CA3268566A1 (en) 2023-04-08 2024-10-17 Rock Biomedical Inc. METHODS AND COMPOSITIONS FOR TARGETED DISTRIBUTION BY POLYMERSOMES
NZ825394A (en) 2023-04-08 2026-03-27 Rock Biomedical Inc Methods and compositions for dendritic cell targeting nano-delivery
CN121175414A (zh) 2023-05-17 2025-12-19 磐石医药生技股份有限公司 Mgat1缺乏细胞及其用途
WO2025222126A1 (en) * 2024-04-19 2025-10-23 Vanderbilt University Var2csa antibodies and methods of use thereof
WO2025255012A1 (en) * 2024-06-03 2025-12-11 Uct Bioscience Co., Ltd. Anti-grp78 antibody, immunoconjugate and uses thereof
US20260144885A1 (en) * 2024-11-22 2026-05-28 Bristol-Myers Squibb Company Anti-lrrc15 antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323840B1 (en) 1999-09-17 2001-11-27 Cts Corporation Surface-mount pointing device
US20040191260A1 (en) * 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
EP1644414B1 (en) 2003-07-22 2015-01-14 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
AU2004260884B2 (en) * 2003-07-22 2009-11-19 Crucell Holland B.V. Binding molecules against SARS-coronavirus and uses thereof
SG159542A1 (en) 2004-11-11 2010-03-30 Crucell Holland Bv Compositions against sars-coronavirus and uses thereof
ES2384497T3 (es) 2005-02-08 2012-07-05 The New York Blood Center, Inc. Anticuerpos monoclonales neutralizantes contra el coronavirus asociado al síndrome respiratorio agudo severo
WO2015080973A1 (en) * 2013-11-26 2015-06-04 Baylor College Of Medicine A novel sars immunogenic composition
JO3701B1 (ar) * 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
CN114456272A (zh) * 2015-04-03 2022-05-10 优瑞科生物技术公司 靶向afp肽/mhc复合体的构建体及其用途
EP3892297A1 (en) 2020-04-09 2021-10-13 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and combinations of peptides for use in immunotherapy against an infection by sars-cov-2 (covid-19)
CN111592595B (zh) * 2020-04-27 2021-02-19 南京医科大学 抗新型冠状病毒SARS-Cov-2的中和性抗体及其应用
CN112300375B (zh) * 2020-11-06 2022-10-25 江苏三木化工股份有限公司 一种水性光固化环氧丙烯酸树脂的制备方法

Also Published As

Publication number Publication date
CA3171139A1 (en) 2021-09-16
AU2021234242A1 (en) 2022-09-29
KR102535195B1 (ko) 2023-05-25
TWI847020B (zh) 2024-07-01
IL296224A (en) 2022-11-01
GB2593023A (en) 2021-09-15
EP3878862A2 (en) 2021-09-15
WO2021183195A1 (en) 2021-09-16
GB202019709D0 (en) 2021-01-27
BR112022017930A2 (pt) 2022-12-13
BR112022017986A2 (pt) 2022-12-13
US11370828B2 (en) 2022-06-28
US20210388066A1 (en) 2021-12-16
CN116096744A (zh) 2023-05-09
US11447541B1 (en) 2022-09-20
WO2021183359A1 (en) 2021-09-16
MX2022011142A (es) 2022-12-13
JP2023517236A (ja) 2023-04-24
AU2020435452A1 (en) 2022-09-29
EP3878862A3 (en) 2021-10-06
KR20220167273A (ko) 2022-12-20
MX2022011141A (es) 2023-01-18
TWI782366B (zh) 2022-11-01
KR20210113936A (ko) 2021-09-17
TW202142564A (zh) 2021-11-16
TW202142563A (zh) 2021-11-16
US12172038B2 (en) 2024-12-24
US20220356229A1 (en) 2022-11-10
IL296333A (en) 2022-11-01
JP2023517234A (ja) 2023-04-24
US20240150438A1 (en) 2024-05-09
CN116096742A (zh) 2023-05-09
US20210292393A1 (en) 2021-09-23
CA3171237A1 (en) 2021-09-16
EP4118110A1 (en) 2023-01-18

Similar Documents

Publication Publication Date Title
MA56074A (fr) Anticorps contre le sars-cov-2 et leurs procédés d'utilisation
MA55025A (fr) Anticorps anti-trem2 et leurs procédés d'utilisation
MA52753A (fr) Anticorps anti-sirpa et leurs procédés d'utilisation
EP3797123A4 (en) ANTI-OX40 ANTIBODIES AND METHODS OF USE
MA52091A (fr) Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
EP3953385A4 (en) CD19 ANTIBODIES AND METHODS OF USE THEREOF
EP4341293A4 (en) ANTI-CD137 ANTIBODIES AND METHODS OF USE
EP3826641A4 (en) COMPOSITION OF FCRN ANTIBODIES AND METHODS OF USE THEREOF
MA55890A (fr) Modulateurs de thr-beta et leurs procédés d'utilisation
MA54089A (fr) Anticorps anti-pd-1 humain et procédés d'utilisation associés
EP4125831A4 (en) KCNT1 INHIBITORS AND METHODS OF USE
EP3873939A4 (en) ANTI-CD79B ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE
EP4061847A4 (en) Anti-b7-h3 monoclonal antibody and methods of use thereof
EP3938400A4 (en) CD22 ANTIBODIES AND METHODS OF USE THEREOF
MA53328A (fr) Anticorps anti-siglec-5 et leurs procédés d'utilisation
EP3867271A4 (en) FORMULATIONS OF ANTI-RSV ANTIBODIES AND METHODS OF USE
EP3710589A4 (en) ANTI-C1S ANTIBODIES AND METHOD OF USING
EP3947452A4 (en) ANTI-NMDA RECEPTOR ANTIBODIES AND METHODS OF USE
EP3966248A4 (en) HUMAN ANTIBODIES TO FEL MUCIN-16 AND THEIR METHODS OF USE
MA51453A (fr) Conjugués anticorps anti-sez6-médicaments et procédés d'utilisation
EP4175624A4 (en) Kcnt1 inhibitors and methods of use
EP4126046A4 (en) Anti-gipr antibody and methods of use thereof
EP3994174A4 (en) MONOSPECIFIC ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
EP3880714A4 (en) ANTIBODIES TO MUCIN-16 AND METHODS OF USE THEREOF
EP4267133A4 (en) KCNT1 INHIBITORS AND METHODS OF USE